Last reviewed · How we verify
NCT04661748: WARD
Automated Alerts of Patient Deterioration vs. Routine Monitoring of High-risk Patients Admitted to Medical Wards
NA trial testing real time alarm of deviating vital signs in Alert Fatigue, Health Personnel in 300 participants. Completed in 31 December 2024.
23 December 2023
Quick facts
| Lead sponsor | University Hospital Bispebjerg and Frederiksberg |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 7 January 2022 |
| Primary completion | 23 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- real time alarm of deviating vital signs
Conditions studied
- Alert Fatigue, Health Personnel — all drugs for Alert Fatigue, Health Personnel →
- Deterioration, Clinical — all drugs for Deterioration, Clinical →
Sponsor
University Hospital Bispebjerg and Frederiksberg
Who can join
18 and older, any sex, with Alert Fatigue, Health Personnel or Deterioration, Clinical. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary aim of the current study is to assess the effect of continuous wireless vital signs monitoring with generation of real-time alerts compared to blinded monitoring without alerts on the cumulative duration of any severely deviating vital signs in patients admitted to general hospital wards with acute medical conditions. Patients admitted with medical conditions represents a large and heterogenous group occupying a substantial part of the total in-patient capacity in the Danish hospitals today. The hypothesize is that continuous vital signs monitoring, and real-time alerts will reduce the cumulative duration of severely deviating vital signs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic value of heart rate variability for risk of serious adverse events in continuously monitored hospital patients.
Aagaard N, Olsen MH, Rasmussen OW, Grønbaek KK, et al · · 2024 · cited 2× · PMID 39162840 · DOI 10.1007/s10877-024-01193-8
Verify or expand the search:
- PubMed search for NCT04661748
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital Bispebjerg and Frederiksberg trials
Trials by the same sponsor.
- NCT07060586 — The Effect of Sphenopalatine Ganglion Block on Headache and Vasalgia · NA · completed
- NCT06911411 — PALLIATIVE ASSESSMENT COHORT IN THE GERIATRIC EMERGENCY SETTING · not yet recruiting
- NCT06405750 — Left Atrial Appendage Arrhythmogenic and Thrombogenic Substrate · NA · recruiting
- NCT06532825 — Cardiac Autonomic Dysfunction As a Sign of Irreversible Advanced Heart Failure · recruiting
- NCT06184581 — Lithium Versus Lamotrigine in Bipolar Disorder, Type II · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04661748 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital Bispebjerg and Frederiksberg
- Last refreshed: 11 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04661748.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing